Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Cellares: The company raised $327 million of Series D venture funding in a deal led by BlackRock Private Equity Partners and Eclipse Capital on June 15, 2026. The company is an operator of an integrated development and manufacturing organization intended to support cell therapy development.Memento Medicines: The company raised $93 million of Series A venture funding in a deal led by Avego Management, Forbion and RA Capital Management on June 18, 2026. The company is a developer of antibody-based therapeutics designed to treat retinal and vascular diseases.Cellanome: The company raised $75.9 million of Series C venture funding from undisclosed investors on June 18, 2026. The company is a developer of an integrative multi-omics platform designed to link live-cell behavior with single-cell transcriptomics.Triveni Bio: The company raised $65 million of Series C venture funding in a deal led by Ascenta Capital and Janus Henderson Investors on June 17, 2026, putting the company’s pre-money valuation at $414.2 million. The company is an operator of a clinical-stage biotechnology business designed to create antibody-based therapies targeting immunological and inflammatory diseases.Cour: The company raised $50 million of Series B venture funding in a deal led by Roche Venture Fund and Lumira Ventures on June 18, 2026, putting the company’s pre-money valuation at $170 million. The company is a developer of an immune-modifying platform intended to achieve antigen-specific tolerance for immune-mediated disease.Vedana Therapeutics: The company raised $46 million of Series A venture funding in a deal led by Westlake Village BioPartners and Canaan Partners on June 17, 2026, putting the company’s pre-money valuation at $13.5 million. The company is a developer of biotechnology therapies designed to address neurological and psychiatric disorders.Spot Biosystems: The company raised $40 million of Series A venture funding from undisclosed investors on June 17, 2026. The company is an developer of extracellular vesicle-based gene delivery technology for non-viral genetic medicines.Sera Medicines: The company raised $38 million of venture funding from undisclosed investors on June 16, 2026. The company is a biologics-focused accelerator that incubates and forms platforms developing protein therapeutics.Rythm Health: The company raised $31 million of venture funding from undisclosed investors on June 18, 2026. The company is a provider of at-home blood testing and biomarker tracking services for health and performance monitoring.Rejuvenate Bio: The company raised $6 million of Series B venture funding in a deal led by VCapital on June 18, 2026. The company is a developer of gene therapies designed for treating chronic age-related diseases.Syntax Bio: The company raised $14.4 million of Series A venture funding from Astellas Venture Management, Mayo Clinic and Sigma Group on June 21, 2026. The company is a developer of CRISPR-based stem cell programming technology for creating cell therapies and organoids.Spineology: The company received $12.6 million of development capital from undisclosed investors on June 16, 2026. The company is a developer of minimally invasive spinal implants and expandable interbody fusion devices.Portal Biotechnologies: The company raised $9 million of venture funding in a deal led by NFX on June 18, 2026. Pear, Undeterred Capital, IA Ventures, IKJ Capital and TechU Ventures also participated in the round. The company is a developer of cell engineering and intracellular delivery technology for cell analytics, drug discovery and cell therapy manufacturing.Kopra Bio: The company raised $9.1 million of venture funding from undisclosed investors on June 16, 2026. The company is a developer of cancer immunotherapies that use engineered biological agents to reprogram tumor cells.CollimateHealth: The company raised EUR 6 million of venture funding from High-Tech Gründerfonds, VP Venture Partners and xista science ventures on June 15, 2026. The company is a developer of a clinically scalable microbeam radiation technology designed for cancer treatment.Nirrin: The company raised $6.7 million of Series B venture funding from undisclosed investors on June 15, 2026, putting the company’s pre-money valuation at $37.3 million. The company is a developer of analytical instruments for real-time monitoring and protein quantitation in bioprocessing.Emblok: The company received $6 million of development capital from undisclosed investors on June 18, 2026. The company is a manufacturer of whole-body embolic protection systems for left-sided cardiovascular procedures, including TAVR.CND Life Sciences: The company raised $4.3 million of venture funding in the form of convertible debt from undisclosed investors on June 16, 2026. The company is a developer of a medical diagnostic platform designed to detect key pathological markers in the peripheral nervous system.DPBIO: The company raised an undisclosed amount of Series B venture funding from Shanghai Science and Technology Innovation Center Equity Investment Fund Management, Shenzhen Nanshan Strategic Emerging Industry Investment and Shanghai Pudong Venture Capital on June 15, 2026. The company is a developer of microfluidics systems for single-cell analysis, antibody discovery and enzyme screening.KiloGen: The company raised an undisclosed amount of venture funding from Zinc on June 15, 2026. The company is a developer of molecular glue and proximity-based therapeutics for targeted protein degradation.Spring Loaded: The company raised an undisclosed amount of venture funding from Plaza Asset Management on June 17, 2026. The company is a manufacturer of spring-assisted knee braces for osteoarthritis, injury recovery and mobility support.

M&A Transactions

Perfuse Therapeutics / Bayer: The company was acquired by Bayer for $2.5 billion on June 17, 2026. The company is an developer of ophthalmic therapies for ischemia-related eye diseases, including glaucoma and diabetic retinopathy.Candid Therapeutics / UCB: The company was acquired by UCB, a subsidiary of Digital Care Transformation, for up to $2.2 billion on June 17, 2026. The company is an operator of a biotechnology research platform designed to create novel, easy-to-administer therapies for autoimmune diseases.Celerion / Thomas H. Lee Partners: The company was acquired by Thomas H. Lee Partners through a $1.8 billion LBO on June 15, 2026. The company is a provider of early-phase clinical research and bioanalytical testing services intended for pharmaceutical and biotechnology companies.Assertio Holdings / Zydus Lifesciences: The company was acquired by Zydus Lifesciences for $166 million on June 16, 2026. The company is a specialty pharmaceutical business focused on commercializing branded medicines, including oncology supportive-care and specialty therapies.Abarca Health / LucyRx: The company reached a definitive agreement to be acquired by LucyRx for an undisclosed amount on June 17, 2026. The company is a pharmacy benefit management provider with a technology platform for claims processing, clinical programs and drug cost management.Arcos / Belmont Medical Technologies: The company was acquired by Belmont Medical Technologies, via its financial sponsors Audax Private Equity and Five Points Capital, through an LBO on June 17, 2026 for an undisclosed amount. The company is a developer of clinical decision support software for blood product tracking, transfusion protocols and resuscitation management.Life Log Technology / Omron: The company was acquired by Omron for an undisclosed amount on June 16, 2026. The company is a developer of Calomeal, an AI-powered nutrition and health management app for tracking diet and exercise.Logis.P / BB Capital Investments: The company was acquired by BB Capital Investments through an LBO on June 16, 2026 for an undisclosed amount. The company is a developer of healthcare software for managing digital patient journeys, patient flow and outpatient clinic workflows.RayThera / Biogen: The company reached a definitive agreement to be acquired by Biogen for up to $1 billion on June 18, 2026. The company is a developer of small-molecule therapies for immunology and inflammatory diseases.Stem Genomics / Clean Cells: The company was acquired by Clean Cells, a subsidiary of Clean Biologics, for an undisclosed amount on June 18, 2026. The company is a provider of genomic stability testing and quality control services for stem cell and cell therapy development.Syncx. / Interlock Equity: The company was acquired by VeloSource, via its financial sponsor Interlock Equity, through an LBO on June 16, 2026 for an undisclosed amount. The company is a developer of a healthcare workforce management platform designed to streamline locums staffing.WillowWood Global / CVC Capital Partners: The company entered into a definitive agreement to be acquired by CVC Capital Partners and its management through an LBO on June 15, 2026 for an undisclosed amount. The company is a manufacturer and distributor of prosthetic and orthotic products.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker